Neptune Medical Announces $97M Series D Financing and Spinout of Jupiter Endovascular
Neptune Medical, a medical device innovator, has announced a successful $97 million Series D financing and the spinout of its subsidiary, Jupiter Endovascular. The financing round saw significant participation from Sonder Capital and Olympus of the Americas, along with other existing and new investors. This strategic move allows Neptune Medical to focus on gastrointestinal robotics, while Jupiter Endovascular will concentrate on its novel endovascular technology platform.
The financing will strengthen Neptune Medical's position in the GI space, as evidenced by the recent appointment of Dr. Fred Moll, a medical robotics pioneer, as Chairman of the Board. Both companies aim to lead innovation in their respective specialties, with Neptune pushing boundaries in GI robotics and Jupiter revolutionizing endovascular therapies.
Neptune Medical, un innovatore nel settore dei dispositivi medici, ha annunciato un finanziamento di Serie D riuscito da 97 milioni di dollari e lo spin-off della sua controllata, Jupiter Endovascular. Il round di finanziamento ha visto una significativa partecipazione da parte di Sonder Capital e Olympus of the Americas, insieme ad altri investitori esistenti e nuovi. Questa mossa strategica consente a Neptune Medical di concentrarsi sui robotica gastrointestinale, mentre Jupiter Endovascular si concentrerà sulla sua piattaforma tecnologica endovascolare innovativa.
Il finanziamento rafforzerà la posizione di Neptune Medical nel settore gastrointestinale, come dimostrato dalla recente nomina del Dr. Fred Moll, un pioniere nella robotica medica, come Presidente del Consiglio. Entrambe le aziende mirano a guidare l'innovazione nelle loro specialità rispettive, con Neptune che oltrepassa i confini nella robotica gastrointestinale e Jupiter che rivoluziona le terapie endovascolari.
Neptune Medical, un innovador en dispositivos médicos, ha anunciado un financiamiento de Serie D exitoso de 97 millones de dólares y la escisión de su subsidiaria, Jupiter Endovascular. La ronda de financiamiento contó con la participación significativa de Sonder Capital y Olympus of the Americas, junto con otros inversores existentes y nuevos. Este movimiento estratégico permite a Neptune Medical centrarse en la robótica gastrointestinal, mientras que Jupiter Endovascular se concentrará en su innovadora plataforma de tecnología endovascular.
El financiamiento fortalecerá la posición de Neptune Medical en el espacio GI, como lo demuestra el reciente nombramiento del Dr. Fred Moll, un pionero en robótica médica, como Presidente de la Junta. Ambas empresas tienen como objetivo liderar la innovación en sus respectivas especialidades, con Neptune empujando los límites en la robótica gastrointestinal y Jupiter revolucionando la terapia endovascular.
Neptune Medical은 의료 기기 혁신 기업으로서 9,700만 달러 규모의 시리즈 D 자금 조달과 자회사인 Jupiter Endovascular의 분사를 발표했습니다. 이번 자금 조달 라운드는 Sonder Capital 및 Olympus of the Americas 등 기존 및 신규 투자자들의 중요한 참여로 이루어졌습니다. 이 전략적 움직임은 Neptune Medical이 위장 로봇 공학에 집중할 수 있도록 하며, Jupiter Endovascular는 혁신적인 혈관 내 기술 플랫폼에 집중할 것입니다.
이번 자금 조달은 최근 의료 로봇 공학의 선구자인 Fred Moll 박사를 이사회 의장으로 임명한 것을 통해 볼 수 있듯이 Neptune Medical의 GI 분야에서의 위치를 강화할 것입니다. 두 회사는 각각의 전문 분야에서 혁신을 이끌어 내고자 하며, Neptune은 GI 로봇 공학의 경계를 넓히고 Jupiter는 혈관 내 치료를 혁신하고자 합니다.
Neptune Medical, un innovateur dans le domaine des dispositifs médicaux, a annoncé un financement de série D réussi de 97 millions de dollars et la scission de sa filiale, Jupiter Endovascular. Ce tour de financement a vu une participation significative de Sonder Capital et d'Olympus of the Americas, ainsi que d'autres investisseurs existants et nouveaux. Ce mouvement stratégique permet à Neptune Medical de se concentrer sur la robotique gastro-intestinale, tandis que Jupiter Endovascular se concentrera sur sa nouvelle plateforme technologique endovasculaire.
Le financement renforcera la position de Neptune Medical dans le domaine GI, comme l'atteste la récente nomination de Dr. Fred Moll, un pionnier de la robotique médicale, au poste de président du conseil. Les deux entreprises visent à diriger l'innovation dans leurs spécialités respectives, Neptune repoussant les limites de la robotique GI et Jupiter révolutionnant les thérapies endovasculaires.
Neptune Medical, ein Innovator im Bereich medizinischer Geräte, hat eine erfolgreiche Serie-D-Finanzierung in Höhe von 97 Millionen Dollar sowie die Ausgliederung seiner Tochtergesellschaft Jupiter Endovascular angekündigt. Die Finanzierungsrunde verzeichnete eine bedeutende Beteiligung von Sonder Capital und Olympus of the Americas zusammen mit anderen bestehenden und neuen Investoren. Dieser strategische Schritt ermöglicht es Neptune Medical, sich auf die gastrointestinale Robotik zu konzentrieren, während Jupiter Endovascular sich auf ihre neuartige endovaskuläre Technologieplattform konzentrieren wird.
Die Finanzierung wird die Position von Neptune Medical im GI-Bereich stärken, was durch die kürzliche Ernennung von Dr. Fred Moll, einem Pionier der medizinischen Robotik, zum Vorsitzenden des Vorstands belegt wird. Beide Unternehmen streben danach, Innovationen in ihren jeweiligen Fachgebieten zu führen, wobei Neptune die Grenzen der GI-Robotik erweitert und Jupiter die endovaskulären Therapien revolutioniert.
- Successful completion of $97 million Series D financing
- Strategic spinout of Jupiter Endovascular subsidiary
- Appointment of medical robotics pioneer Dr. Fred Moll as Chairman of the Board
- Focused approach on GI robotics and endovascular technologies
- Significant investment from Sonder Capital and Olympus of the Americas
- None.
The $97 million Series D financing for Neptune Medical is a significant milestone, demonstrating strong investor confidence in the company's potential. This substantial funding, coupled with the strategic spinout of Jupiter Endovascular, positions Neptune Medical for focused growth in the GI robotics sector. The involvement of Sonder Capital and Olympus of the Americas as major investors adds credibility to Neptune's vision.
The spinout strategy allows for more efficient capital allocation and specialized management focus. This move could potentially unlock value for shareholders by creating two distinct entities with clear market focuses. However, investors should closely monitor how this separation affects operational synergies and overall company valuation.
The appointment of Dr. Fred Moll, a pioneer in medical robotics, as Chairman of the Board, further strengthens Neptune's position in the GI robotics market. This leadership addition could accelerate innovation and market penetration, potentially leading to increased market share and revenue growth in the competitive medical device industry.
The spinout of Jupiter Endovascular from Neptune Medical represents a strategic move to optimize research and development in two distinct medical fields: GI robotics and endovascular treatments. This separation allows for more focused innovation and potentially faster product development cycles in both areas.
Neptune's shift towards GI robotics, backed by Dr. Fred Moll's expertise, suggests a promising future in minimally invasive gastrointestinal procedures. This could lead to improved patient outcomes, reduced recovery times and potentially lower healthcare costs. The GI robotics market is still in its early stages, presenting significant growth opportunities.
For Jupiter Endovascular, the dedicated focus on novel endovascular technology could accelerate advancements in treating vascular diseases. This specialization may lead to breakthrough therapies and devices, potentially addressing unmet needs in areas such as stroke prevention, aneurysm treatment and peripheral artery disease management.
The successful $97 million Series D financing for Neptune Medical, coupled with the spinout of Jupiter Endovascular, signals strong market confidence in both the GI robotics and endovascular technology sectors. This move aligns with the trend of specialization in the medical device industry, allowing each entity to better address specific market needs and compete more effectively.
The GI robotics market, which Neptune is now focusing on, is projected to grow significantly in the coming years due to increasing prevalence of GI disorders and demand for minimally invasive procedures. Neptune's strategic positioning, backed by Dr. Fred Moll's expertise, could potentially capture a substantial market share.
The endovascular market, which Jupiter will target, is also experiencing rapid growth, driven by an aging population and rising incidence of cardiovascular diseases. Jupiter's dedicated focus on this sector could lead to innovative solutions and potential market leadership.
Olympus 's investment suggests potential strategic partnerships or future acquisition opportunities, which could further enhance market penetration and technology development for Neptune Medical.
This financing will strengthen Neptune Medical as a gastrointestinal-focused company expanding into robotics for GI disease, as evidenced by the recent appointment of medical robotics pioneer Dr. Fred Moll as Chairman of the Board. It will also enable Jupiter Endovascular to focus on its novel endovascular technology platform.
"Neptune Medical is thrilled to announce the successful closure of our Series D financing and the spinout of Jupiter Endovascular. These significant milestones allow us to sharpen our focus on GI robotics while empowering Jupiter to drive innovation in endovascular treatments," said Alex Tilson, Founder and CEO of Neptune Medical. "We are grateful to our investors for their unwavering support and confidence in our vision."
Dr. Moll commented, "The spinout of Jupiter Endovascular is a strategic move that aligns with our long-term goals. With dedicated resources and leadership, Jupiter is well-positioned to revolutionize endovascular therapies. Meanwhile, Neptune will continue to push the boundaries in GI robotics, delivering transformative solutions to patients and healthcare providers. We intend for both companies to lead the way in innovating within their respective specialties."
Chief Strategy Officer for Olympus, Gabriela Kaynor, added, "We are excited to participate in this financing round for Neptune Medical. We believe Neptune's innovative approach to endoscopy has the potential to elevate the standard of care by improving patient outcomes."
About Neptune Medical
Neptune Medical is at the forefront of developing advanced medical devices, with a primary focus on gastrointestinal robotics. The company's mission is to enhance patient outcomes through innovative technology and collaborative partnerships.
About Jupiter Endovascular
Jupiter Endovascular, a spinout of Neptune Medical, is developing a new class of endovascular procedures to bring the precision and control of direct surgical access to catheter-based interventions.
About Olympus Corporation
At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states.
For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world.
For more information, visit www.olympus-global.com and follow our global X account: @Olympus_Corp.
About Sonder Capital
Sonder’s team of veteran investors, innovators, founder-operators, and company builders is known not only for their individual achievements, but also for their collective success in creating, funding, and leading private and public companies that have transformed healthcare for millions of patients globally — including Intuitive Surgical (NASDAQ:ISRG), Procept Biorobotics (NASDAQ:PRCT), Shockwave Medical, Auris Health, and Reflexion Medical, among others. Sonder’s extensive network of limited partners is global and includes industry leaders, high-net-worth individuals, and leading family offices focused on investing in game-changing healthcare technologies. Sonder Capital was co-founded in 2019 by healthcare luminaries Jay Watkins and Fred Moll, M.D.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240815402386/en/
MEDIA CONTACT:
Michelle McAdam, Chronic Communications, Inc.
michelle@chronic-comm.com, (310) 902-1274
Source: Neptune Medical
FAQ
What was the amount of Neptune Medical's Series D financing?
Which subsidiary did Neptune Medical spin out?
Who are the major investors in Neptune Medical's Series D financing?
What is Neptune Medical's new focus after the spinout?
Who was appointed as the Chairman of the Board for Neptune Medical?
